Evaluation of ghrelin, nesfatin-1 and irisin levels of serum and brain after acute or chronic pentylenetetrazole administrations in rats using sodium valproate

Erkeç, Özlem Ergül; Algül, Şermin; Kara, Mehmet

doi:10.1080/01616412.2018.1503992

Cited by 13 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, in previous studies, significant alterations were reported in ghrelin [15][16][17][18] , irisin 20 , FNDC5/irisin 18 , and nesfatin-1 16,18 levels. Despite this, there is also lack of evidence of whether these four neuropeptide levels are altered with drug resistant temporal lobe epilepsy (DRTLE) or not.…”

Section: Introductionmentioning

confidence: 62%

“…Increased 15 or decreased 16,17 ghrelin levels have been reported in studies on epilepsy patients. In a previous study, significantly decreased ghrelin levels in the brain and serum were found in acute PTZ-induced seizures; and PTZ kindling models, in rats 18 . It was suggested that ghrelin has antiepileptic 27 and neuroprotective 28 properties.…”

Section: Discussionmentioning

confidence: 79%

“…Nesfatin-1 is a recently identified neuropeptide, produced in different areas of the brain 21 . Increased nesfatin-1 levels have been reported in clinical 16 and animal studies 18 . Vasoactive intestinal peptide (VIP), a neuropeptide that contains 28 amino acids, is expressed in different areas of the brain 22 .…”

Section: Introductionmentioning

confidence: 95%

“…Ghrelin is described as a new anticonvulsant 12 , pleiotropic 13 , and orexigenic peptide, known to be expressed in the brain 14 . Alterations in ghrelin levels have been reported both in clinical [15][16][17] and animal studies 18 . Irisin is defined as a myokine, which is produced in skeletal muscle with exercise 19 .…”

Section: Introductionmentioning

confidence: 97%

“…In addition, FNDC5, the precursor of irisin, is present in the brain 19 . Significant alterations in serum levels of irisin 20 and FNDC5/ irisin 18 have been reported. Nesfatin-1 is a recently identified neuropeptide, produced in different areas of the brain 21 .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of serum ghrelin, nesfatin-1, irisin, and vasoactive intestinal peptide levels in temporal lobe epilepsy patients with and without drug resistance: a cross-sectional study

Erkeç

Milanlıoğlu

Kömüroğlu

et al. 2021

Rev. Assoc. Med. Bras.

Self Cite

View full text Add to dashboard Cite

OBJECTIVE: Epilepsy is a common disorder that affects the nervous systems of 1% of worldwide population. In epilepsy, one-third of patients are unresponsive to current drug therapies and develop drug-resistant epilepsy. Alterations in ghrelin, nesfatin-1, and irisin levels with epilepsy were reported in previous studies. Vasoactive intestinal peptide is among the most common neuropeptides in the hippocampus, which is the focus of the seizures in temporal lobe epilepsy. However, there is also lack of evidence of whether these four neuropeptide levels are altered with drug resistant temporal lobe epilepsy or not. The aim herein was the evaluation of the serum levels of nesfatin-1, ghrelin, irisin, and Vasoactive intestinal peptide in drug-resistant temporal lobe epilepsy patients and temporal lobe epilepsy (TLE) without drug resistance, and to compare them to healthy controls. METHODS:This cross-sectional study group included 58 temporal lobe epilepsy patients (24 with drug resistant temporal lobe epilepsy and 34 with temporal lobe epilepsy who were not drug-resistant) and 28 healthy subjects. Nesfatin-1, ghrelin, irisin, and Vasoactive intestinal peptide serum levels were determined using enzyme-linked immunosorbent assay. RESULTS:The serum ghrelin levels of patients with drug resistant temporal lobe epilepsy were seen to have significantly decreased when compared to those of the control group (p<0.05). Serum nesfatin-1, vasoactive intestinal peptide, and irisin levels were seen to have decreased in the drug resistant temporal lobe epilepsy group when compared to those of the control and temporal lobe epilepsy groups; however, the difference was non-significant (p>0.05). CONCLUSIONS:The results herein suggested that ghrelin might contribute to the pathophysiology of drug resistant temporal lobe epilepsy. However, further studies are needed to confirm this hypothesis.

show abstract